Clinical trials: Vaccine Preventable Disease
Preventable Disease, Vaccine
Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies
The goal of this pilot demonstration and evaluation project is to determine the acceptability and feasibility of a co-payment model among the public and providers and assess whether a co-payment model in community pharmacies in…
- Trial name
- NCT06489964
- Testing
- Co-payment Model - Step 1, Co-payment Model - Step 2, Co-payment Model - Step 3
- Where
- 2 sites in Canada
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network
Hepatitis A, Hepatitis A Virus
Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV
Hepatitis A virus (HAV) remains a common infection in Thai children. Two HAV vaccines are available: inactivated vaccine (I-HAV, 2 doses) and live-attenuated vaccine (L-HAV, single dose), but neither is included in Thailand's…
- Conditions
- Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases
- Trial name
- HAV-2 (NCT06978621)
- Testing
- Inactivated hepatitis A vaccine (I-HAV)
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
COVID-19, Vaccine Adverse Reaction
Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
The objective of this observational case-crossover study is to evaluate the effectiveness, safety and immunogenicity of the second booster dose in the elderly.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases
- Trial name
- Plus_Booster (NCT05283902)
- Testing
- ChAdOx1 nCoV-19 or Comirnaty or Janssen COVID-19 Vaccine
- Where
- Brazil
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Federal University of Espirito Santo
Hepatitis A, Hepatitis A Virus
Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents
Hepatitis A virus (HAV) remains a common infection among Thai children. Two types of HAV vaccines are available in Thailand: an inactivated vaccine (I-HAV, administered in two doses 6 months apart) and a live-attenuated vaccine…
- Conditions
- Hepatitis A, Hepatitis A Virus, Vaccine-Preventable Diseases
- Trial name
- NCT07032610
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
HPV Infection, Vaccine Preventable Disease
Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania
Add-Vacc is an unblinded cluster-randomised trial (CRT) with two arms: (i) the national HPV vaccination programme (girls aged ~14 years, control arm) and (ii) the national programme plus single-dose male HPV vaccination given to…
- Trial name
- Add-Vacc (NCT04953130)
- Testing
- Gardasil® HPV vaccine
- Where
- Tanzania
- Volunteers
- 10,400 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Influenza
Project IMPACT Immunizations (IMProving America's Communities Together) Scaled Demonstration
The primary objective of this study is to evaluate how implementing an innovative care model that provides the pharmacist access to a patient's vaccine history at the point-of-care impacts the pharmacist's ability to identify…
- Trial name
- NCT03372967
- Testing
- Vaccine administration by a pharmacist, Unmet vaccination needs identified and met, Vaccination forecast review and patient education
- Where
- 22 sites in United States
- Volunteers
- 6,234 people, healthy volunteers welcome
- Sponsor
- American Pharmacists Association Foundation
Diphtheria, Tetanus
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease
This is a randomized cross-sectional study of the Swedish population. Blood samples will be collected from a subpopulation in order to estimate the age specific sero-prevalence of the Swedish population for diseases included in…
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- Sero 2007 (NCT00932269)
- Where
- Sweden
- Volunteers
- 5,400 people, healthy volunteers welcome
- Sponsor
- Swedish Institute for Infectious Disease Control
Streptococcus Pneumonia, Vaccine Preventable Disease
Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age
The current study provides data necessary to evaluate the safety and immunogenicity of Serum Institute of India's PNEUMOSIL® [Pneumococcal Polysaccharide Conjugate Vaccine Adsorbed (10-Valent)] in Healthy Vietnamese Infants and…
- Trial name
- PNEUMOSIL (NCT05140720)
- Testing
- PNEUMOSIL®
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Vabiotech
Pertussis, Diphtheria
Maternal Immunization With Tetanus Toxoid, Reduced Diphtheria Toxoid, Reduced-dose (2 µg) Recombinant Pertussis Vaccine (TdaP2gen) and Its Effect on the Immune Response in Thai Infants up to 15-18 Months Old
Pertussis remains a major global public health problem. In Thailand, pertussis vaccination is recommended during pregnancy at 20-32 weeks' gestation, together with routine childhood diphtheria-tetanus-pertussis vaccination…
- Conditions
- Pertussis, Diphtheria, Tetanus, Vaccine-Preventable Diseases
- Trial name
- M-PRIME (NCT07621341)
- Testing
- Maternal TdaP2gen vaccine, Infant Acellular Pertussis-containing Vaccine, Infant Whole-cell Pertussis-containing Vaccine
- Where
- Thailand
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
Vaccine-Preventable Diseases, Typhoid Fever
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
The goal of this clinical trial is to explore the coadministration of oral typhoid fever (Vivotif®) and cholera (Dukoral®) vaccines in healthy volunteers aged 18-65 years.
- Conditions
- Vaccine-Preventable Diseases, Typhoid Fever, Cholera
- Trial name
- NCT06104345
- Testing
- Oral typhoid fever vaccine, Oral cholera vaccine
- Where
- Finland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases
Culturally Tailored HPV Psychoeducational Multimedia Intervention
Community members ages 18 - 45 years old from the El Paso, Texas, U.S.-Mexico Border Region will be recruited to compare psychoeducational multimedia interventions focused on the human papillomavirus (HPV).
- Conditions
- Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention, Adherence, Patient
- Trial name
- NCT06098690
- Testing
- Culturally Tailored Multimedia Psychoeducational HPV Intervention, General HPV Multimedia Psychoeducational Control Group
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
Healty Volunteers, Preventable Disease, Vaccine
A Phase 2 Bridging Study to Assess the New Formulation of ETVAX
This is a phase 2,prospective double-blind, randomized, parallel-group study with the aim to demonstrate non-inferiority, in terms of immunogenicity, between the wet formulation and a newly developed partially dried formulation…
- Trial name
- NCT05178134
- Testing
- Etvax
- Where
- Sweden
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Scandinavian Biopharma AB
Covid19, Vaccine Preventable Disease
Study of Gam-COVID-Vac in Adolescents
Double-blind, placebo-controlled study with open dose selection period for safety assessment, tolerance and immunogenicity of the drug "GamKOVID-Vac M, a combined vector vaccine for prevention of coronavirus infection caused by…
- Trial name
- OLSTAD (NCT04954092)
- Testing
- Gam-COVID-vac M
- Where
- 2 sites in Russia
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Influenza
Project IMPACT Immunizations (IMProving America's Communities Together)
The primary objective of this study is to evaluate how implementing an innovative care model that provides the pharmacist access to a patient's vaccine history at the point-of-care impacts the pharmacist's ability to identify…
- Trial name
- NCT02584036
- Testing
- Vaccine administration by a pharmacist, Unmet vaccination needs identified and met, Vaccination forecast review and patient education
- Where
- 8 sites in United States
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- American Pharmacists Association Foundation
Vaccine Preventable Disease
Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations
A cluster randomized trial will be conducted prior to widespread vaccine availability to the general public. Community-informed COVID-19 vaccine messages will be disseminated to participants.
- Trial name
- CERC (NCT04765839)
- Testing
- Educational, culturally appropriate COVID-19 messages
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Shingles, Herpes Zoster
Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers
This is a randomized, active-controlled, dose-escalation multi-center study of 2 doses (Day 1 and Week 8) of an investigational herpes zoster (HZ) vaccine (Z-1018), combining herpes zoster antigen- (gE) with a Toll-like receptor…
- Conditions
- Shingles, Herpes Zoster, Vaccine-Preventable Diseases
- Trial name
- NCT05245838
- Testing
- Z-1018, Shingrix
- Where
- 4 sites in Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
COVID-19, Vaccine-Preventable Diseases
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
- Trial name
- SHIELD (NCT06633835)
- Testing
- protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novavax
Vaccine-Preventable Diseases, Herpes Zoster
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
This clinical trial is to study protective efficacy and safety of a recombinant herpes zoster vaccine (LZ901) and sponsored by Beijing Luzhu Biotechnology Co., Ltd.
- Trial name
- NCT06088745
- Testing
- Recombinant Herpes Zoster Vaccine
- Where
- China
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Beijing Luzhu Biotechnology Co., Ltd.
Vaccine-Preventable Diseases, Herpes Zoster
Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.
- Trial name
- NCT06137755
- Testing
- CVI-VZV-001, Shingrix
- Where
- 2 sites in South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Aribio Lab Co., Ltd.
Shingles, Herpes Zoster
Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over
This is a randomized, active-controlled, observer-blinded, dose-escalation multi-center trial of 2 doses of an investigational HZ vaccine (Z-1018) in approximately 764 healthy adults.
- Conditions
- Shingles, Herpes Zoster, Vaccine-Preventable Diseases
- Trial name
- NCT06569823
- Testing
- Z-1018, Shingrix
- Where
- 16 sites in Australia, New Zealand
- Volunteers
- 764 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation